Home
News
Create
Screeners
Insights
Fischer Medical Ventures
35.
04
+0.44
(+1.27%)
Market Cap
₹2,272.40 Cr
PE Ratio
57.73
Industry
Chemicals
Buy
Sell
Company Performance:
1D
+1.27%
1M
-14.26%
6M
-22.48%
1Y
-54.84%
5Y
-54.84%
View Company Insights
Latest news about Fischer Medical Ventures
WFNS Innovation & Technology Committee Announces Landmark Collaboration with Time Medical International Ventures, Subsidiary of Fischer Medical Ventures
6 days ago
The WFNS Innovation & Technology Committee announced a landmark collaboration with Time Medical International Ventures (India) Pvt. Ltd., a wholly owned subsidiary of Fischer Medical Ventures Limited, on May 14, 2026. This marks the first time in the Committee's history that it has formally partnered with an industry participant. The collaboration will focus on advanced neurosurgical technologies, medical imaging, and global training initiatives. Both organisations aim to set a new benchmark for ethical, innovation-led partnerships in global neurosurgical care.
Fischer Medical Ventures Submits SEBI Compliance Certificate for Quarter Ended March 31, 2026
Apr 09, 2026
Fischer Medical Ventures Files SAST Disclosure Following Rs. 10.53 Crore Warrant Conversion
Apr 01, 2026
Fischer Medical Ventures Appoints Balaji Gandla as Company Secretary and Compliance Officer
Mar 24, 2026
Fischer Medical Ventures Opens Special Window for Physical Share Transfer Re-lodgement
Mar 12, 2026
More news about Fischer Medical Ventures
04
Mar 26
Fischer Medical Ventures: Invests 75% In PT Fischer Pariko Medical Ventures Shares
Fischer Medical Ventures has expanded into Southeast Asian markets through its wholly owned subsidiary FMV Global Innovations Pte Limited, which acquired a 75% stake in PT Fischer Pariko Medical Ventures. The Indonesian company, incorporated in October 2024, operates in healthcare equipment wholesale distribution, with the investment requiring no direct cash consideration or regulatory approvals.
06
Feb 26
Fischer Medical Ventures Promoter Pledges 30 Lakh Shares to HDFC Bank for Working Capital
Fischer Medical Ventures promoter Shankar Varadharajan pledged 30,00,000 equity shares (4.63% of total share capital) to HDFC Bank on February 5, 2026, as collateral for a ₹40 crores loan. The pledged shares, valued at ₹109.59 crores, provide a security cover ratio of 2.74 times the loan amount. The funds will be used for working capital requirements of the company's wholly owned subsidiary to strengthen group operations.
02
Feb 26
Fischer Medical Ventures Reports Strong Q3FY26 Performance with Revenue Growth
Fischer Medical Ventures delivered impressive Q3FY26 consolidated performance with revenue reaching ₹10,109.52 lakhs and achieving net profit of ₹1,923.48 lakhs against previous year's loss. The company also announced key organizational changes including resignation of Company Secretary and Malaysian subsidiary restructuring initiative.
21
Jan 26
Fischer Medical Ventures Approves Internal Group Reorganisation of Foreign Subsidiary Shares
Fischer Medical Ventures Limited announced that its Executive Business Committee approved the transfer of shares in foreign subsidiary PellucidCare Health Innovations Pte Ltd (Singapore) to wholly owned subsidiary FlynnCare Health Innovations Private Limited as part of internal group reorganisation. The transfer aims to improve administrative and operational efficiency while maintaining unchanged ultimate ownership, control, and economic interest in the foreign subsidiary, with no material impact on consolidated financials.
02
Jan 26
Fischer Medical Ventures Limited Updates Board Committee Composition in Regulatory Filing
Fischer Medical Ventures Limited disclosed updated board committee compositions on January 02, 2026, detailing the structure of Audit, Nomination & Remuneration, and Risk Management committees. The committees comprise independent directors, executive management, and senior officers, with Mr. Khairy Jamaluddin Abu Bakar chairing two committees and Ms. Svetlana Rao Raviwada leading the Risk Management Committee.
28
Oct 25
Fischer Medical Ventures Reports Robust Q2 Growth with 46-Fold Increase in Net Profit
Fischer Medical Ventures, a medical technology company, reported a significant financial performance boost in Q2. Net profit surged to 139.00 million rupees from 3.00 million rupees year-over-year, a 46-fold increase. Revenue more than doubled to 863.00 million rupees from 397.00 million rupees. The company also announced board changes, appointing Mr. Chan Sing En as Additional Non-Executive Independent Director and recommending Tan Sri Dato' Dr. Syed Jalaludin as Independent Director, both for five-year terms subject to shareholder approval.
Fischer Medical Ventures
35.
04
+
0.
44
(+
1.
27
%)
1 Year Returns:
-54.84%
Industry Peers
Tata Chemicals
729.95
(-
0.
85
%)
Deepak Fertilisers & Petrochemicals
1,317.80
(-
0.
51
%)
Gujarat Narmada Valley Fert & Chem
520.45
(-
4.
67
%)
Gujarat Alkalies & Chemicals
717.25
(+
2.
77
%)
TANFAC Industries
2,120.00
(+
0.
89
%)
GHCL
455.40
(+
0.
02
%)
Chemplast Sanmar
225.54
(-
2.
09
%)
Grauer & Weil
64.04
(-
0.
88
%)
Thirumalai Chemicals
212.08
(+
4.
46
%)
Fischer Medical Ventures
35.04
(+
1.
27
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO